Patents by Inventor Xianqun FAN

Xianqun FAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240069027
    Abstract: A use of nitrogen-doped carbon fluorescent quantum dots in preparation of aerobic glycolysis detection products is provided. The carbon-nitrogen fluorescent quantum dots are selected from one or more of C3N4 quantum dots, C2N quantum dots, and C3N quantum dots. The aerobic glycolysis detection products are reagents, based on a final volume of the reagents, the reagents comprise the carbon-nitrogen fluorescent quantum dots with a final concentration of 1 ?g/mL-1 mg/mL. The present disclosure realizes fluorescent labeling of NAD+ in living cells using the carbon-nitrogen fluorescent quantum dots, thus achieving fluorescent labeling and imaging of cells having aerobic glycolysis, which has the advantages of low cost, high efficiency, rapidity, and high accuracy.
    Type: Application
    Filed: December 28, 2021
    Publication date: February 29, 2024
    Applicants: SHANGHAI NINTH PEOPLE'S HOSPITAL, SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE, SHANGHAI INSTITUTE OF MICROSYSTEM AND INFORMATION TECHNOLOGY, CHINESE ACADEMY OF SCIENCES
    Inventors: JIPENG LI, SIWEI YANG, GUQIAO DING, HUIFANG ZHOU, XIANQUN FAN
  • Publication number: 20210260091
    Abstract: The present invention provides use of salidroside and a derivative thereof in preparation of an inhibitor medicament for treating diseases, such as opthmalmic fibrosis, caused by abnormalities of extracellular matrix proteins. The present invention treats and prevents diseases associated with ocular fibrosis such as glaucoma, by inhibiting the expression of extracellular matrix proteins in the eye to prevent fibrosis. The present invention further provides use of an inhibitor medicament for treating and preventing diseases, such as opthmalmic fibrosis, caused by abnormalities of extracellular matrix proteins, the inhibitor medicament comprising an effective amount of salidroside and a derivative thereof as active ingredients.
    Type: Application
    Filed: June 14, 2019
    Publication date: August 26, 2021
    Applicants: Shanghai Ninth People's Hospital, Shanghaijiaotong University School of Medicine, Shanghai Ninth People's Hospital, Shanghaijiaotong University School of Medicine
    Inventors: Tao GUO, Xianqun FAN, Yuchen FAN, Li GUO, Iok-Hou Pang, Jiahong WEI